Canada Markets close in 3 hrs 1 min
  • S&P/TSX

    20,531.63
    -12.48 (-0.06%)
     
  • S&P 500

    4,359.37
    +32.86 (+0.76%)
     
  • DOW

    34,198.26
    +37.48 (+0.11%)
     
  • CAD/USD

    0.7824
    -0.0028 (-0.3599%)
     
  • CRUDE OIL

    86.97
    +0.36 (+0.42%)
     
  • BTC-CAD

    47,097.40
    +405.10 (+0.87%)
     
  • CMC Crypto 200

    839.04
    -3.41 (-0.40%)
     
  • GOLD FUTURES

    1,784.50
    -10.50 (-0.58%)
     
  • RUSSELL 2000

    1,931.96
    +0.67 (+0.03%)
     
  • 10-Yr Bond

    1.7860
    -0.0210 (-1.16%)
     
  • NASDAQ

    13,533.83
    +181.04 (+1.36%)
     
  • VOLATILITY

    29.80
    -0.69 (-2.26%)
     
  • FTSE

    7,466.07
    -88.24 (-1.17%)
     
  • NIKKEI 225

    26,717.34
    +547.04 (+2.09%)
     
  • CAD/EUR

    0.7012
    -0.0030 (-0.43%)
     

Treace Announces Grant of U.S. Patent and Allowance of U.S. Patent Application on Bone Positioner Technology for Bunion Correction

  • Oops!
    Something went wrong.
    Please try again later.
·2 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • TMCI

PONTE VEDRA, Fla., Nov. 30, 2021 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (Nasdaq: TMCI), a commercial-stage orthopaedic medical device company driving a paradigm shift in the surgical treatment of hallux valgus (commonly known as bunions) through its Lapiplasty® 3D Bunion Correction™ procedure, announced today that the United States Patent and Trademark Office granted to the Company U.S. Patent No. 11,185,359, titled “Bone Positioning Guide,” and also issued a Notice of Allowance for the Company’s pending U.S. Patent Application No. 17/353,431, titled “Bone Positioning and Preparing Guide Systems and Methods.”

The granted patent relates generally to techniques, including for use in bunion correction surgery, for moving the first metatarsal with a positioning instrument. The allowed patent application relates generally to techniques for correcting a bunion deformity involving the use of a bone preparation guide and a positioning instrument. The newly granted patent and allowed patent application expand Treace’s comprehensive patent coverage on instrumented bunion correction techniques with particular emphasis on metatarsal bone positioning instrumentation, a product category Treace pioneered through its innovative development efforts.

“We are pleased that the Patent Office continues to recognize the novel advances made by Treace Medical. The addition of this recent patent grant and the notice of allowance further strengthen our intellectual property position and highlight our commitment to innovation in advancing the surgical treatment of bunion patients,” said John T. Treace, CEO of Treace Medical.

Treace actively protects its innovations through patenting and is gratified that the United States Patent and Trademark Office and patent agencies worldwide continue to recognize the novelty of Treace’s contributions to the field. The Company has a global portfolio of over 35 granted patents and 60 pending patent applications, including over 30 pending US patent applications. Additional details on Treace’s patent coverage can be found at www.treace.com/patents.

About Treace Medical Concepts
Treace Medical Concepts, Inc. is a commercial-stage orthopaedic medical device company with the goal of advancing the standard of care for the surgical management of bunion deformities and related midfoot correction. Bunions are complex 3-dimensional deformities that originate from an unstable joint in the middle of the foot. Treace has pioneered and patented the Lapiplasty® 3D Bunion Correction™ system - a combination of instruments, implants, and surgical methods designed to correct all 3 planes of the bunion deformity and secure the unstable joint, addressing the root cause of the bunion and helping patients get back to their active lifestyles. Treace recently expanded its offering with the Adductoplasty™ Midfoot Correction System, designed for reproducible correction of the midfoot which could provide further support to hallux valgus patients. For more information, please visit www.treace.com.

Contacts:
Treace Medical Concepts
Mark L. Hair
Chief Financial Officer
mhair@treace.net
(904) 373-5940

Investors:
Gilmartin Group
Lynn Lewis or Vivian Cervantes
IR@treace.net


Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting